Neuropsychiatric involvement in systemic lupus erythematosus (NPSLE) is considered as one of the major manifestations of the disease. Epilepsy has been documented in about 10% of patients with systemic lupus erythematosus (SLE). It is well known that vascular damage in SLE occurs because of multiple mechanisms including hypercoagulation. It has been recently reported that in SLE patients raised levels of homocysteine are associated with arterial thrombosis. Hyperhomocysteinaemia is a condition due to both genetic and non-genetic factors. The most common genetic defect in homocysteine metabolism is a decreased activity of a common 5,10-methylenetetrahydrofolate reductase (MTHFR) variant (677C→T, a thermolabile form).
INTRODUCTION
Systemic lupus erythematosus (SLE) is characterized by the production of a wide range of autoantibodies that play a role in the generation of organ damage. Criteria for neuropsychiatric involvement in SLE (NPSLE) have been recently defined 1 . NPSLE has been emphasized as one of the major manifestations, since the first descriptions of the disease, and it is among the leading causes of SLE morbidity and mortality [2] [3] [4] . The reported prevalence of NPSLE has been as high as 75% but a prevalence of approximately 20% appears to be more representative. Epilepsy has been documented in about 10% of patients with SLE 5, 6 .
It is well known that vascular damage in SLE occurs through multiple mechanisms, including immune complex deposition and vasculitis, hypertension, hyperlipidaemia and hypercoagulation. In 1998, Fijnheer et al. 7 , in a retrospective cohort study on 175 SLE patients, reported that raised levels of homocysteine (Hcy) are associated with arterial thrombosis. Hyperhomocysteinaemia is a condition due to both genetic and non-genetic factors. A common 5,10-methylene-tetrahydrofolate reductase (MTHFR) variant (677C→T, a thermolabile form) may induce elevated homocysteine plasma concentrations. In SLE patients the distribution of MTHFR genotypes is 50% for the homozygous wild type, 42% for the heterozygous, and 8% for the homozygous mutant 7 . This mutation has been recently reported also in epileptic non-SLE patients with a frequency ranging from 23% for homozygosity and 52% for heterozygosity 8 .
We are carrying out a study on the thrombophilic factors in SLE patients with neuropsychiatric manifestations. In a cohort of 55 patients, who fulfilled the American College of Rheumatology (ACR) criteria for SLE classification, six had seizures (10.9%). In the present paper we intend to report the peculiar results obtained by a coagulation screening in our SLE patients suffering from epilepsy. In fact, the distribution of MTHFR mutation was not consistent with the above mentioned data in the literature, since it was present in all epileptic patients of our cohort.
Case 1
A 43-year-old woman described a three year history of weakness, arthralgia, Raynaud's phenomenon, sicca syndrome, swollen hands and feet, malar butterfly erythema and alopecia. Since the age of 12 she has been complaining of complex partial seizures with secondary generalization and frontal lobe epilepsy was diagnosed. EEG revealed fronto-temporal spikes in the right lobe and treatment with phenytoin was started.
Immunological studies revealed positive of antinuclear antibodies (ANA) and anti double stranded-DNA (ds-DNA). Notwithstanding that ACR criteria were satisfied, drug related SLE could not be excluded. Phenytoin therapy was stopped, but clinical conditions and laboratory findings did not improve. Anticonvulsant treatment was replaced with phenobarbitone and immunosuppressive therapy was started.
A coagulation study revealed positivity for anticardiolipin IgG antibodies (aCL) and heterozygosity for 677C→T MTHFR mutation (Table 1) .
Case 2
A 26-year-old woman presented with menorrhagia, fever, dyspnoea and chest constriction, weakness and diffuse arthralgia. From the age of 18 partial seizures, with secondary generalization, repeatedly occurred. Visual evoked potentials (VEPs) showed bilateral abnormalities. EEG revealed abnormal, repetitive, rhythmic activity in the right occipital area, consistent with epilepsy; in addition, magnetic resonance imaging (MRI) of the brain showed cortical and subcortical atrophy without focal lesions. On the basis of the clinical features and laboratory data, the patient fulfilled the ACR criteria for SLE classification. Corticosteroid therapy was started.
Carbamazepine treatment was suspended because of an increasing titre of ANA, and valproic acid treatment was started. A coagulation study showed a decrease of S protein levels, lupus anticoagulant (LAC) and aCL positivity (IgG/IgM), and homozygosity for 677C→T MTHFR mutation (Table 1) .
Case 3
A 49-year-old woman had a 36-year history of SLE. During the course of her disease she developed three episodes of venous thrombosis and a spontaneous abortion at the 15th week of gestation. LAC positivity and presence of anticardiolipin IgG and IgM antibodies were found. A diagnosis of secondary antiphospholipid syndrome was made.
When she was 47-year-old she developed temporal lobe epilepsy. The EEG showed epileptic activity on the right temporal lobe. She started treatment with valproic acid. Brain MRI and VEPs were performed, but they were unremarkable.
A further coagulation study confirmed LAC and aCL IgG/IgM positivity and revealed heterozygosity for 677C→T MTHFR mutation (Table 1) .
Case 4
A 17-year-old man, since the age of 2, complained of complex partial seizures with secondary generalization. EEG revealed frontal spikes in the right lobe, and frontal seizure semeiology was found. Treatment with phenobarbitone was started. From the age of 4 the patient fulfilled the clinical and laboratory ACR criteria for SLE diagnosis (erythema, arthralgias, lymphopaenia, anaemia, ANA and anti ds-DNA positivity). Immunosuppressive treatment was started and notwithstanding the anticonvulsant therapy, generalized seizures repeatedly occurred.
Thrombophilic screening showed heterozygosity for 677C→T MTHFR mutation (Table 1) .
Case 5
A 39-year-old woman had a 23-year history of SLE. At the age of 20 she presented with pleuritis; three months later she had a reversible ischaemic attack. When she was 26-year-old she suffered from generalized seizures. The EEG showed fronto-temporal activity in the left lobe. Brain MRI showed subcortical focal lesions in the left frontal lobe. Treatment with phenobarbitone was started.
A coagulation study revealed LAC positivity and heterozygosity for 677C→T MTHFR mutation (Table 1) .
Case 6
A 49-year-old woman presented SLE from the age of 26. She had a history of a spontaneous abortion at the 5th month of gestation. When she was 28-year-old, after a premature birth, she developed complex partial seizures. EEG showed frontal spikes in the right lobe, and a frontal seizure semeiology was found. She was treated with carbamazepine and phenobarbitone. Moreover, on the basis of LAC and aCL IgG/IgM positivity, a diagnosis of secondary antiphospholipid syndrome was made. When she was 34-year-old she presented with a right hemiparesis. CT scan and MRI documented a condition of subarachnoid haemorrhage. At the age of 47 she developed a transverse myelitis. The coagulation study showed LAC and aCL IgG/IgM positivity, and heterozygosity for 677C→T MTHFR mutation (Table 1) .
DISCUSSION
The enzyme activity of 5,10-methylenetetrahydrofolate reductase (MTHFR) catalyzes the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. In humans, 5-methyltetrahydrofolate, a major circulating form of folate, is the primary methyl donor for remethylation of homocysteine to methionine. This means that a low folate status is associated with increased homocysteine (Hcy) plasma levels. Genetic deficiency of MTHFR may cause severe hyperhomocysteinemia and cardiovascular diseases. In 1988, Kang et al. 9 described a thermolabile variant of MTHFR that is associated with decreased enzyme activity and mildly elevated Hcy plasma levels. In 1995, Frosst et al. 10 identified a 677C→T mutation in which a cytidine residue at nucleotide position 677 in the gene coding for the MTHFR enzyme is replaced by thymidine. Although severe hyperhomocysteinemia (>150 mmol L −1 ) causes atherosclerosis and life-threatening arterial and venous thromboembolic events in young subjects 11 , mild Hcy elevation (>15 mmol L −1 ) in the adult population is associated with increased risk of myocardial infarction, stroke, peripheral arterial disease and venous thrombosis [12] [13] [14] [15] [16] [17] . The 677C→T mutation is the most frequent in caucasians; homozygosity of the thermolabile MTHFR mutant allele occurs commonly in 5% to 15% of the population, and the heterozygosity is over 40% 18 . Moreover, this mutation shows ethnic differences and it is rare in AfroAmericans. Homozygous subjects appear to have an exaggerated hyperhomocysteinemic response to the depletion of folic acid and the folic acid depletion may increase the risk for vascular diseases [19] [20] [21] .
Homozygosity for MTHFR 677C→T mutation is more frequent in epileptic patients compared with healthy controls (23% vs. 12%) and heterozygosity is about 52% 8 . Anticonvulsant drugs, such as phenytoin, phenobarbitone, primidone and carbamazepine, have been shown to decrease serum folate levels 8 . However, the mechanism by which anticonvulsants induce folate deficiency is still unknown. Plasma levels of Hcy and serum folate were inversely correlated in a study on epileptic patients 22 . The high frequency of the MTHFR TT genotype and defective folate metabolism due to anticonvulsants are independent risk factors for occlusive vascular diseases and could play a role in epileptogenesis. It is not clear whether impaired Hcy metabolism is related to epileptogenesis or to alteration of seizure threshold 8 . However, Lipton and co-workers 23 showed that Hcy may have excitotoxicity to neurons as an agonist of the glutamate binding site of the N-methyl-Daspartate (NMDA) receptors. In the rat model, it was demonstrated that an NMDA receptor antagonist is protective against seizures induced by Hcy 24 .
In SLE patients the distribution of the MTHFR genotypes is 50% for the homozygous wild type, 42% for heterozygous, and 8% for the homozygous mutant 7 . In our study the thermolabile MTHFR mutant allele occurred in all of the six SLE patients with epileptic symptoms: the homozygosity form was documented in one patient (16.7%), and the heterozygosity forms in five of them (83.3%). Moreover, we observed a decrease of S protein levels in one case, high titre positivity (IgG and IgM) of aCL antibodies in three patients and a low titre positivity (IgG) in one patient, and LAC positivity in four cases (Table 1) .
In the present series, epileptic manifestations were the SLE onset symptom for three patients (cases no. 1, 2 and 4), appeared during the active disease in two cases (no. 5 and 6), and occurred during a period of clinical remission of SLE in one patient (case no. 3). Indeed, as reported in the literature, epilepsy can precede the onset of SLE or occurs at any time during its course; it can occur during active SLE or during a quiescent period and may appear as well as other neurologic events in the same individual 7 . Two patients showed simple partial seizures (cases no. 2 and 3), three patients showed complex partial seizures (cases no. 1, 4 and 6) and one primary generalized seizures (case no. 5). Three patients displayed a secondary generalization of partial seizures (cases no. 1, 2 and 4). We found in all cases frontotemporal seizure semeiology, cognitive impairment and psychopathological disorders.
As previously reported, some anticonvulsant drugs may determine a low folate status and increased levels of Hcy, probably by inducing hepatic microsomal enzymes 8 . Corticosteroid treatment may also increase Hcy plasma concentrations directly through its hormonal effect 7 . In our study we have observed the presence of MTHFR mutation in six SLE patients affected by epilepsy: the Hcy plasma levels were within the normal range in all of them, although they had been taking both anticonvulsants and prednisolone. It is well known that neurological involvement in SLE occurs because of multiple mechanisms, such as thrombotic events and neurotoxic and oxidative damage. We believe that an impaired Hcy metabolism, and/or the presence of antiphospholipid antibodies and LAC, could play a role in epileptogenesis or could be related to an alteration of the seizure threshold.
